Shahrzad Tehranian

Shahrzad Tehranian

Auto-generated profile, based on publicly available information

Shahrzad Tehranian

Mashhad University of Medical Sciences

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2013 in Pediatric Radiology
Verified
Journal Article
Closed access
PDF file
HKHamid Reza Kianifar
Hamid Reza Kianifar
STShahrzad Tehranian
Shahrzad Tehranian
PSPardis Shojaei
Pardis Shojaei
ZAZohreh Adinehpoor
Zohreh Adinehpoor
RSRamin Sadeghi
Ramin Sadeghi
AKAlireza S. Keshtgar
Alireza S. Keshtgar

21 January 2017 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
FKFahime Khozeimeh
Fahime Khozeimeh
FAFarahzad Jabbari Azad
Farahzad Jabbari Azad
YOYaghoub Mahboubi Oskouei
Yaghoub Mahboubi Oskouei
MJMajid Jafari
Majid Jafari
STShahrzad Tehranian
Shahrzad Tehranian
PLPouran Layegh
Pouran Layegh

1 December 2021 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
SBShane A. Bobart
Shane A. Bobart
HHHeedeok Han
Heedeok Han
STShahrzad Tehranian
Shahrzad Tehranian
AVAn S. De Vriese
An S. De Vriese
JRJuan Carlos Leon Roman
Juan Carlos Leon Roman
FFFernando C. Fervenza
Fernando C. Fervenza
Background and objectives: Kidney biopsy is the current gold standard to diagnose membranous nephropathy. Approximately 70%–80% of patients with primary membranous nephropathy have circulating anti-phospholipase A2 receptor antibodies. We previously demonstrated that in proteinuric patients with preserved eGFR and absence of associated conditions (e.g., autoimmunity, malignancy, infection, drugs, and paraproteinemia), a positive anti-phospholipase A2 receptor antibody test by ELISA and immunofluorescence assay confirms the diagnosis of membranous nephropathy noninvasively. These data have not been externally validated. Design, setting, participants, & measurements: The clinical and pathologic characteristics of patients with a positive anti-phospholipase A2 receptor antibody test at the Mayo Clinic, the University Hospital Vall D’Hebron (Barcelona), and the Columbia University Medical Center (New York) were retrospectively reviewed. Biopsy findings and presence or absence of a potential associated condition were assessed. Results: From a total of 276 patients with positive anti-phospholipase A2 receptor serology, previously reported patients (n=33), kidney transplant recipients (n=9), pediatric patients (n=2), and patients without kidney biopsy (n=69) were excluded. Among the 163 remaining patients, associated conditions were identified in 47 patients, and 15 patients had diabetes mellitus. All 101 patients of the final cohort had a primary diagnosis of membranous nephropathy on kidney biopsy. In the 79 patients with eGFR≥60 ml/min per 1.73 m2, none of the biopsy findings altered diagnosis or management. Among the 22 patients with decreased eGFR, additional findings included superimposed acute interstitial nephritis (n=1). Conclusions: In patients with preserved eGFR and absence of associated conditions or diabetes, a positive anti-phospholipase A2 receptor test by either ELISA >20 RU/ml or a positive immunofluorescence assay confirms the diagnosis of membranous nephropathy, precluding the requirement for a kidney biopsy.

1 April 2013 in Lung Cancer
Verified
Journal Article
Closed access
AKAli Taghizadeh Kermani
Ali Taghizadeh Kermani
RBReza Bagheri
Reza Bagheri
STShahrzad Tehranian
Shahrzad Tehranian
PSPardis Shojaee
Pardis Shojaee
RSRamin Sadeghi
Ramin Sadeghi
DKDavid N. Krag
David N. Krag

17 December 2019 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
STShahrzad Tehranian
Shahrzad Tehranian
KSKhaled Shawwa
Khaled Shawwa
Kianoush KashaniKianoush Kashani
Kianoush Kashani
Fluid overload, a critical consequence of acute kidney injury (AKI), is associated with worse outcomes. The optimal fluid removal rate per day during continuous renal replacement therapy (CRRT) is unknown. The purpose of this study is to evaluate the impact of the ultrafiltration rate on mortality in critically ill patients with AKI receiving CRRT. This was a retrospective cohort study where we reviewed 1398 patients with AKI who received CRRT between December 2006 and November 2015 at the Mayo Clinic, Rochester, MN, USA. The net ultrafiltration rate (UFNET) was categorized into low- and high-intensity groups (<35 and ≥35 mL/kg/day, respectively). The impact of different UFNET intensities on 30-day mortality was assessed using logistic regression after adjusting for age, sex, body mass index, fluid balance from intensive care unit (ICU) admission to CRRT initiation, Acute Physiologic Assessment and Chronic Health Evaluation III and sequential organ failure assessment scores, baseline serum creatinine, ICU day at CRRT initiation, Charlson comorbidity index, CRRT duration and need of mechanical ventilation. The mean ± SD age was 62 ± 15 years, and 827 (59%) were male. There were 696 patients (49.7%) in the low- and 702 (50.2%) in the high-intensity group. Thirty-day mortality was 755 (54%). There were 420 (60%) deaths in the low-, and 335 (48%) in the high-intensity group (P < 0.001). UFNET ≥35 mL/kg/day remained independently associated with lower 30-day mortality (adjusted odds ratio = 0.47, 95% confidence interval 0.37–0.59; P < 0.001) compared with <35 mL/kg/day. More intensive fluid removal, UFNET ≥35 mL/kg/day, among AKI patients receiving CRRT is associated with lower mortality. Future prospective studies are required to confirm this finding.

1 March 2020 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
STShahrzad Tehranian
Shahrzad Tehranian
MKMatthew Klinge
Matthew Klinge
MSMelissa Saul
Melissa Saul
MMMichele Morris
Michele Morris
BDBrenda Diergaarde
Brenda Diergaarde
RSRobert E. Schoen
Robert E. Schoen